Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | APAF1 | O14727 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3984108 | 1.00 | TDP1 (0.48) | TDP1HSD17B10APAF1CYP3A4CHRM2 | |
| SCHEMBL3044206 | 1.00 | TDP1 (0.48) | TDP1HSD17B10APAF1CYP3A4CHRM2 | |
| Hydrochloric Acid SCHEMBL8783045 | 0.97 | MEN1 (0.50) | TDP1HSD17B10APAF1CYP3A4CHRM2 | |
| SCHEMBL9641540 | 0.81 | ALOX5 (0.52) | KCNH2ACP3ALDH1A1 | |
| SCHEMBL283979 | 0.78 | SIGMAR1 (0.61) | HSD17B10APAF1CYP3A4CHRM2ADRA1A | |
| SCHEMBL28869351 | 0.78 | CYP3A4 (0.52) | HSD17B10APAF1CYP3A4CHRM2ADRA1A | |
| SCHEMBL30763462 | 0.78 | SIGMAR1 (0.61) | HSD17B10APAF1CYP3A4CHRM2ADRA1A | |
| SCHEMBL1200137 | 0.78 | SIGMAR1 (0.61) | HSD17B10APAF1CYP3A4CHRM2ADRA1A | |
| SCHEMBL8437895 | 0.78 | SIGMAR1 (0.61) | HSD17B10APAF1CYP3A4CHRM2ADRA1A | |
| SCHEMBL2390659 | 0.78 | CYP3A4 (0.52) | HSD17B10APAF1CYP3A4CHRM2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118516915-A | Longitudinal connection analysis method and design for bridge concrete anti-collision guardrail | 陕西省交通规划设计研究院有限公司 | 2024-08-20 | — | — | CN | claimed |
| CN-118308960-A | Vertical connecting structure of bridge concrete anti-collision guardrail and strength calculation method thereof | 北京中交华安科技有限公司 | 2024-07-09 | — | — | CN | claimed |
| CN-118295006-A | System for calibrating DDL-1 type gas radon instrument based on AlphaGUARD P F radon instrument | 云南省地震局信息中心 | 2024-07-05 | — | — | CN | claimed |
| CN-216132780-U | Diffusion type sampling emanometer response capability testing device | 赵影 | 2022-03-25 | — | — | CN | claimed |
| US-8084630-B2 | Process for the synthesis of ramelteon and its intermediates | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-12-27 | — | — | US | claimed |
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-11-12 | — | — | US | claimed |
| EP-2098519-A1 | Process for the synthesis of ramelteon and its intermediates | Teva Pharmaceutical Industries Ltd. (IL) | 2009-09-09 | — | — | EP | claimed |
| EP-2069320-A2 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | Teva Pharmaceutical Industries Ltd. (IL) | 2009-06-17 | — | — | EP | claimed |
| WO-2009056993-A2 | A PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-07 | — | — | WO | claimed |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | US | claimed |
| WO-2008151170-A2 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-12-11 | — | — | WO | claimed |
| US-20250188325-A1 | POSITIVELY CHARGED ADHESIVES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY | 2025-06-12 | — | — | US | disclosed |
| CN-118795532-A | Moisture-flow-resistant radon source and preparation method and application thereof | 上海市计量测试技术研究院(中国上海测试中心、华东国家计量测试中心、上海市计量器具强制检定中心) | 2024-10-18 | — | — | CN | disclosed |
| CN-118759573-A | Gas-flowing radon source and application thereof | 上海市计量测试技术研究院(中国上海测试中心、华东国家计量测试中心、上海市计量器具强制检定中心) | 2024-10-11 | — | — | CN | disclosed |
| US-20240321472-A1 | REMOVING A RADIOACTIVE NOBLE GAS FROM A GAS VOLUME | SCK CEN (BE) | 2024-09-26 | — | — | US | disclosed |
| EP-2069320-A2 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | Teva Pharmaceutical Industries Ltd. (IL) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009056993-A2 | A PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-07 | — | — | WO | disclosed |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | US | disclosed |
| WO-2008151170-A2 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2008-12-11 | — | — | WO | disclosed |
| US-20060020004-A1 | Isoxazolidine compounds for treatment of bacterial infections | INFINITY PHARMACEUTICALS, INC. (US) | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281176-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | TDP1 2994/4885HSD17B10 146/4885APAF1 4833/4885 |
| US-20060020004-A1 | Isoxazolidine compounds for treatment of bacterial infections | QDPR, NQO2, SQLE | TDP1 2846/4885HSD17B10 3222/4885APAF1 2628/4885 |
| US-20090069581-A1 | PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | CYP2B6, UGT1A6, CYP2A6 | TDP1 2771/4885HSD17B10 204/4885APAF1 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.